Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The gold standard for tuberculosis (TB) treatment support requires directly observed therapy (DOT), which means a trained health worker observes the patient swallow each dose of medication every day for 2 months. Despite the practice of DOT in Malaysia, 1 in 20 patients are loss-to-follow-up and non-adherent to treatment. Sub-optimal adherence due to poor treatment acceptability and social desirability promotes TB treatment failure, disease relapse, on-going transmission, drug resistance, and death. Telemedicine offers a flexible and less invasive option to support TB treatment adherence. Despite 97% internet and smartphone penetration rates, the practical implementation of digital adherence strategies to support and monitor TB treatment remains untested in Malaysia. The investigators propose to design, implement, and measure the effectiveness of a comprehensive, pharmacist-led digital solution for TB treatment support called CARE-TB which combines a package of asynchronous video-observed therapy, digital reminders, telecounselling and e-learning. In this multi-method effectiveness-implementation (Type 2) study using the Exploration, Preparation, Implementation and Sustainment (EPIS) framework, the investigators aim 1) To identify patient and provider-level facilitators and barriers to CARE-TB adoption via qualitative evaluation and to design a stakeholder-informed implementation strategy, (2) To assess effectiveness of CARE-TB strategy by evaluating (i) implementation outcomes, (ii) patient health outcomes, and (iii) service outcomes, and (3) To evaluate the cost-effectiveness of CARE-TB compared to standard of care from a societal perspective. This study will leverage digital platforms to expand the reach of TB adherence support, enhance adherence to TB treatment and improve treatment completion rates, while utilising existing personnel and resources in among the busiest TB treatment centres in the country.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Standard care arm | Active Comparator | Directly observed therapy (healthcare or caretaker-based) |
|
| CARE-TB arm | Experimental | CARE-TB package includes pharmacist-led asynchronous video observed therapy, digital medication reminders, telecounselling and e-learning for patients. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| CARE-TB digital adherence package | Behavioral | CARE-TB package includes pharmacist-led asynchronous video observed therapy, digital medication reminders, telecounselling and e-learning for patients. |
| Measure | Description | Time Frame |
|---|---|---|
| Medication adherence (Binary outcome) | Completed ≥ 80% scheduled observations during the 8 weeks following enrolment. | 8 weeks following enrollment |
| Measure | Description | Time Frame |
|---|---|---|
| Adherence rate (Continuous outcome) | Proportion of doses observed over 8 weeks (Dose observed divided by total observable doses prescribed) | 8 weeks following enrolment |
| Proportion of TB treatment completion, death, loss to follow up, and hospitalization |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Reena Rajasuriar | University of Malaya | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Sungai Buloh Hospital | Sungai Buloh | Selangor | 47000 | Malaysia |
Individual participant data that underlie the results reported following deidentification.
Beginning 3 months following publication and no end date.
Investigators whose proposed used of data has been approved by independent review. Proposals should be submitted to kohhuimoon@moh.gov.my. To gain access, a data sharing agreement must be signed.
Not provided
Not provided
| ID | Term |
|---|---|
| D014376 | Tuberculosis |
| D055985 | Latent Tuberculosis |
| ID | Term |
|---|---|
| D009164 | Mycobacterium Infections |
| D000193 | Actinomycetales Infections |
| D016908 | Gram-Positive Bacterial Infections |
| D001424 | Bacterial Infections |
Not provided
Not provided
| ID | Term |
|---|---|
| D062405 | Motivational Interviewing |
| D003376 | Counseling |
| D004522 | Educational Status |
| D059039 | Standard of Care |
| ID | Term |
|---|---|
| D037001 | Directive Counseling |
| D008605 | Mental Health Services |
| D004191 | Behavioral Disciplines and Activities |
| D006296 | Health Services |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Standard Care | Behavioral | Directly observed therapy at any government healthcare facility (by nurses) or at home (by caretaker) |
|
|
Proportion of patients completing TB treatment, died, are lost to follow-up or hospitalized during TB treatment |
| From enrolment till 6 months or treatment completion/ termination |
| TB cure rate | Proportion of microbiological TB clearance (e.g. AFB smear/ MTB PCR/ MTB culture) | At 6 months of treatment |
| Adverse event reporting | Number of adverse events or adverse drug reactions reported during TB treatment | From enrolment till 6 months of treatment |
| EQ-5D-5L Health-related Quality of Life (HRQoL) | HRQoL will be assessed using the EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire. Unit of Measure: EQ-5D index score (range: -0.281 to 1.000 based on country-specific value set) Interpretation: Higher scores indicate better health-related quality of life. | At baseline, 2 months and 6 months of treatment |
| SF-12 Health-related Quality of Life (HRQoL) | The 12-Item Short Form Survey (SF-12) will be used to assess participants' health-related quality of life. Two summary scores will be generated: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). The scoring scale is from 0 to 100, the higher the score the better the health related quality of life. | At baseline and 2 months of treatment |
| Implementation Outcomes: Acceptability, Feasibility, Appropriateness (Quantitative measure) | Implementation outcomes will be assessed using the combined Acceptability of Intervention Measure (AIM), Feasibility of Intervention Measure (FIM), and Intervention Appropriateness Measure (IAM) questionnaire. Unit of Measure: Total and individual mean scores on 5-point Likert scale (1 = completely disagree, 5 = completely agree) Scoring: Each subscale consists of 4 items; subscale scores range from 4 to 20 Interpretation: Higher scores indicate greater perceived acceptability, feasibility, or appropriateness of the intervention | At 2 months and 6 months of treatment |
| Perceived acceptability, feasibility, and fit of the intervention (Qualitative measure) | Semi-structured qualitative interviews and focus group discussions will explore participants' perceptions of the intervention's acceptability, feasibility, and fit. Unit of Measure: Thematic findings from qualitative analysis Interpretation: Interview data will be thematically coded and analyzed to identify key barriers, facilitators, and contextual factors. | After 6 months of implementation phase |
| Adoption rate | Rate of uptake (number of participants who agree to use the CARE TB strategy divided by total number offered) | Through study completion, an average of 1 year |
| Patient fidelity to intervention | Rate of drop-out (count of individuals who fulfill any of the following: withdraw from the study, switch arms, appointment no-show) | 8 weeks following enrolment |
| Healthcare providers (HCP) fidelity to intervention | Rate of reengagement attempt (count of reminders sent to reestablish VOT over total number of missed VOT appointments) | 8 weeks following enrolment |
| D001423 | Bacterial Infections and Mycoses |
| D007239 | Infections |
| D000085343 | Latent Infection |
| D005159 | Health Care Facilities Workforce and Services |
| D003153 | Community Health Services |
| D012959 | Socioeconomic Factors |
| D011154 | Population Characteristics |
| D019984 | Quality Indicators, Health Care |
| D011787 | Quality of Health Care |
| D006298 | Health Services Administration |
| D017530 | Health Care Quality, Access, and Evaluation |